Zacks upgrades Werewolf Therapeutics stock to Strong Buy

Published on 10/14/2026 at 01:47 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Zacks gives Werewolf Therapeutics stock a Strong Buy rank on October 13, 2026. Estimate revisions rose 17.60 percent over three months overall.

Estimate revisions shape the outlook

Zacks ranked Werewolf Therapeutics number 1 on October 13, 2026 after a 17.60 percent rise in its consensus estimate.
The proposed Ambros merger assigns USD 500.00 million to Ambros and USD 47.50 million to Werewolf.
Werewolf Therapeutics had a USD 48.20 million market capitalization as of October 13, 2026.
The next earnings date is listed as October 30, 2026.

HOWL, US95075A1079, Illustration mit AI erstellt.

Werewolf Therapeutics stock received a Zacks Rank number 1, or Strong Buy, on October 13, 2026, after the consensus estimate rose 17.60 percent over three months. The upgrade arrives while the company is preparing a proposed combination with Ambros Therapeutics and a major private financing.

Three dates shape the deal

On August 21, 2026, Werewolf Therapeutics and Ambros announced an all-stock merger agreement alongside an oversubscribed USD 150.00 million private placement, according to StockTitan.

Werewolf filed the registration statement on Form S-4 on September 22, 2026, according to the SEC. The filing registers securities for the business combination and identifies Werewolf Therapeutics as the issuer.

On October 13, 2026, Zacks said its estimate for fiscal 2026 earnings per share was negative USD 0.89 and that the consensus estimate had increased 17.60 percent over three months.

What does dilution mean?

The merger terms put the valuation gap at the center of the transaction. Gunpowder Alerts reported on September 22, 2026 that Ambros was valued at USD 500.00 million versus USD 47.50 million for Werewolf.

The same filing analysis put legacy Werewolf holders at approximately 6.40 percent of the combined company, while Ambros holders would own approximately 72.00 percent and PIPE investors approximately 21.60 percent. Those percentages show why shareholder approval and Nasdaq listing confirmation remain central conditions of the transaction.

Next report date is October 30

ToAlpha lists October 30, 2026 as the next earnings date for Werewolf Therapeutics. The company develops conditionally activated immune therapies through its PREDATOR platform, including WTX-124 and WTX-330.

Market value remains below USD 50 million

Werewolf Therapeutics had a market capitalization of USD 48.20 million as of October 13, 2026. The valuation makes the proposed USD 150.00 million financing materially larger than the company's market value, while the merger's ownership terms remain the central issue for existing shareholders.

Market context: Market report Nasdaq Composite.